Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 14/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 13/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436698 | 0.90 | CDK9 (0.55) | CDK9CCNT1SIGMAR1 | |
| SCHEMBL3434596 | 0.86 | CCNT1 (0.52) | CDK9CCNT1SIGMAR1DRD2LMNA | |
| SCHEMBL3434233 | 0.84 | CDK9 (0.52) | CDK9CCNT1SIGMAR1LMNAPMP22 | |
| SCHEMBL3436505 | 0.83 | CCNT1 (0.47) | CDK9CCNT1DRD2 | |
| SCHEMBL3436391 | 0.82 | KDM4E (0.45) | CDK9CCNT1SIGMAR1WNT3ADRD2 | |
| SCHEMBL521178 | 0.81 | ADAM10 (0.49) | CDK9CCNT1LMNA | |
| SCHEMBL3436712 | 0.81 | CDK9 (0.42) | CDK9CCNT1SIGMAR1WNT3AATM | |
| SCHEMBL3551951 | 0.80 | ATM (0.41) | CDK9CCNT1SIGMAR1DRD2ATM | |
| SCHEMBL16422890 | 0.80 | MAPT (0.44) | CDK9CCNT1LMNA | |
| SCHEMBL3436711 | 0.77 | CCNT1 (0.43) | CDK9CCNT1SIGMAR1WNT3ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | CDK9 648/4885CCNT1 3047/4885SIGMAR1 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.